Kidney dysfunction has a major impact on the effect of idarucizumab for dabigatran reversal.

Athavale, Akshay; Jamshidi, Nazila; Roberts, Darren M

Athavale, Akshay; Jamshidi, Nazila; Roberts, Darren M.

Athavale A; From the Department of Renal Medicine, Concord Repatriation General Hospital (AA), Concord Clinical School, Faculty of Medicine and Health, University of Sydney (AA), Drug Health Services and Clinical Pharmacology and Toxicology, Royal Prince Alfred Hospital (AA, NJ, DMR), New South Wales Poisons Information Centre, Sydney Children's Hospital Network (NJ, DMR), Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, New South Wales, Australia (DMR), Department of Renal Medicin

Eur J Anaesthesiol ; 38(9): 1005-1006, 2021 09 01.

Article en En | MEDLINE | ID: mdl-34397529

Asunto(s)

Anticuerpos Monoclonales Humanizados; Dabigatrán; Antitrombinas/efectos adversos; Dabigatrán/efectos adversos; Humanos; Riñón

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Dabigatrán Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google